TEST:

Lunit SCOPE Genotype Predictor

Furthermore, across a multi-scanner test set (n=2,261), EGFR mutation predictions were concordant in 90.4% of cases among five of six frequently used slide scanners. This validation across diverse clinical settings represents a vital step towards the application of artificial intelligence (AI)-based digital pathology tools in routine clinical practice to augment molecular EGFR mutation screening.

"Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a strategic collaboration with AstraZeneca, a leading pharmaceutical company, to develop AI-powered digital pathology solutions. The solution in focus is Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor (EGFR) mutations."